Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) were up 9.2% on Tuesday . The company traded as high as $12.63 and last traded at $12.00. Approximately 1,346,581 shares changed hands during mid-day trading, an increase of 79% from the average daily volume of 750,984 shares. The stock had previously closed at $10.99.
A number of analysts recently weighed in on ADMS shares. HC Wainwright set a $45.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 6th. BidaskClub raised shares of Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 17th. Leerink Swann reissued an “outperform” rating on shares of Adamas Pharmaceuticals in a report on Friday, October 19th. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, ValuEngine lowered shares of Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company. Adamas Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $35.11.
The company has a current ratio of 8.95, a quick ratio of 8.74 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $323.30 million, a P/E ratio of -3.02 and a beta of 1.53.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) EPS for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.12. Adamas Pharmaceuticals had a negative net margin of 617.27% and a negative return on equity of 106.74%. The firm had revenue of $10.61 million during the quarter, compared to analyst estimates of $10.10 million. As a group, equities research analysts predict that Adamas Pharmaceuticals Inc will post -5.37 earnings per share for the current year.
In other Adamas Pharmaceuticals news, CFO Alfred G. Merriweather sold 1,665 shares of Adamas Pharmaceuticals stock in a transaction on Friday, September 21st. The shares were sold at an average price of $19.18, for a total transaction of $31,934.70. Following the completion of the sale, the chief financial officer now owns 25,460 shares of the company’s stock, valued at approximately $488,322.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 24.60% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC grew its holdings in Adamas Pharmaceuticals by 318.2% during the 2nd quarter. Millennium Management LLC now owns 342,180 shares of the specialty pharmaceutical company’s stock worth $8,839,000 after acquiring an additional 260,360 shares during the period. Macquarie Group Ltd. grew its holdings in Adamas Pharmaceuticals by 12.5% during the 2nd quarter. Macquarie Group Ltd. now owns 1,310,310 shares of the specialty pharmaceutical company’s stock worth $33,846,000 after acquiring an additional 145,412 shares during the period. SCP Investment LP grew its holdings in Adamas Pharmaceuticals by 4.9% during the 2nd quarter. SCP Investment LP now owns 210,191 shares of the specialty pharmaceutical company’s stock worth $5,429,000 after acquiring an additional 9,732 shares during the period. State Board of Administration of Florida Retirement System acquired a new stake in Adamas Pharmaceuticals during the 2nd quarter worth $203,000. Finally, Bank of New York Mellon Corp grew its holdings in Adamas Pharmaceuticals by 12.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 246,352 shares of the specialty pharmaceutical company’s stock worth $6,363,000 after acquiring an additional 27,696 shares during the period. 95.65% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/06/adamas-pharmaceuticals-adms-trading-up-9-2.html.
Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Featured Story: Liquidity
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.